Viridian Therapeutics, Inc.
VRDN
Viridian Therapeutics, Inc., a biotechnology company, develops treatments for patients suffering from serious diseases. It develops VRDN-001, a humanized monoclonal anti-IGF-1R antibody that is in Phase 1/2 clinical trial for the treatment of thyroid eye disease (TED); VRDN-002, an IGF-1R antibody, which is in Phase 1 clinical trial; and VRDN-003, a therapeutic antibody targeting IGF-1R for the trā¦ read more
Healthcare
Biotechnology
11 years
USD
Exclusive to Premium users
Price
per share adjusted in USD$31.72
Price+0.99%
$0.31
1Y
Price
Market Cap
$2.575b
Mid
Price/Earnings 3y Avg5y Avg
-
Premium
Premium
Financials Overview
Key metrics over the past few years-48.1%
EBITDA Margin-49.0%
Net Profit Margin-120.1%
Free Cash Flow MarginRevenue
$70.789m
+23340.1%
1y CAGR+7751.3%
3y CAGR+5803.4%
5y CAGREarnings
-$301.971m
-11.9%
1y CAGR-36.1%
3y CAGR-43.0%
5y CAGREPS
-$3.02
+24.1%
1y CAGR+4.5%
3y CAGR+13.7%
5y CAGRBook Value
$502.970m
$577.138m
Assets$74.168m
Liabilities$23.820m
DebtDebt to Assets
4.1%
-0.1x
Debt to EBITDAFree Cash Flow
-$326.338m
-40.2%
1y CAGR-53.8%
3y CAGR-58.5%
5y CAGRFinancial Reports
Earnings and other important metrics. Amounts in USD.No items found.
Press Releases
Statements and updates from the company